Key result
Conventional chemotherapeutics and newer anti-cancer signaling inhibitors carry a substantial risk of cardiovascular side effects, necessitating timely diagnosis and surveillance to prevent long-term damage.
Population
Cancer patients undergoing treatment
Design
Review
Authors
Loading...
May warrant integrated cardio-oncology surveillance during cancer therapy; leaves open standardized protocols for novel agents.
Cardio-oncology requires balancing life-saving cancer treatments with the management of associated cardiovascular side effects.
Suter et al. (2012) conducted a review in Cancer and cardiovascular side effects. Cancer drugs (chemotherapeutics and signaling inhibitors) was evaluated. Conventional chemotherapeutics and newer anti-cancer signaling inhibitors carry a substantial risk of cardiovascular side effects, necessitating timely diagnosis and surveillance to prevent long-term damage.